Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, characterized by neurofibrillary tangles (NFTs), senile plaques (SPs), and a progressive loss of neuronal cells in selective brain regions. Rab10, a small Rab GTPase involved in vesicular trafficking, has recently been identified as a novel protein associated with AD. Interestingly, Rab10 is a key substrate of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine protein kinase genetically associated with the second most common neurodegenerative disease Parkinson’s disease. However, the phosphorylation state of Rab10 has not yet been investigated in AD. Here, using a specific antibody recognizing LRRK2-mediated Rab10 phosphorylation at the amino acid residue threonine 73 (pRab10-T73), we performed immunocytochemical analysis of pRab10-T73 in hippocampal tissues of patients with AD. pRab10-T73 was prominent in NFTs in neurons within the hippocampus in all cases of AD examined, whereas immunoreactivity was very faint in control cases. Other characteristic AD pathological structures including granulovacuolar degeneration, dystrophic neurites and neuropil threads also contained pRab10-T73. The pRab10-T73 immunoreactivity was diminished greatly following dephosphorylation with alkaline phosphatase. pRab10-T73 was further found to be highly co-localized with hyperphosphorylated tau (pTau) in AD, and demonstrated similar pathological patterns as pTau in Down syndrome and progressive supranuclear palsy. Although pRab10-T73 immunoreactivity could be noted in dystrophic neurites surrounding SPs, SPs were largely negative for pRab10-T73. These findings indicate that Rab10 phosphorylation could be responsible for aberrations in the vesicle trafficking observed in AD leading to neurodegeneration.
AlloulK, SauriolL, KennedyW, LaurierC, TessierG, NovoselS, ContandriopoulosA (1998) Alzheimer’s disease: A review of the disease, its epidemiology and economic impact. Arch Gerontol Geriatr27, 189–221.
2.
SmithMA (1998) Alzheimer disease. Int Rev Neurobiol42, 1–54.
3.
CzechC, TrempG, PradierL (2000) Presenilins and Alzheimer’s disease: Biological functions and pathogenic mechanisms. Prog Neurobiol60, 363–384.
4.
FraserPE, YangDS, YuG, LevesqueL, NishimuraM, ArawakaS, SerpellLC, RogaevaE, St George-HyslopP (2000) Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta1502, 1–15.
5.
TanahashiH, TabiraT (2000) Alzheimer’s disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum Mol Genet9, 2281–2289.
ItoG, KatsemonovaK, TonelliF, LisP, BaptistaMA, ShpiroN, DuddyG, WilsonS, HoPW, HoSL, ReithAD, AlessiDR (2016) Phos-tag analysis of Rab10 phosphorylation by LRRK2: A powerful assay for assessing kinase function and inhibitors. Biochem J473, 2671–2685.
19.
ZhuXW, RottkampCA, BouxH, TakedaA, PerryG, SmithMA (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol59, 880–888.
20.
NunomuraA, PerryG, PappollaMA, WadeR, HiraiK, ChibaS, SmithMA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease. J Neurosci19, 1959–1964.
21.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189.
22.
YaoPJ (2004) Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer’s disease. Trends Neurosci27, 24–29.
23.
ColemanP, FederoffH, KurlanR (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology63, 1155–1162.
24.
TerryRD, MasliahE, SalmonDP, ButtersN, DeTeresaR, HillR, HansenLA, KatzmanR (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol30, 572–580.
25.
DeKoskyST, ScheffSW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Ann Neurol27, 457–464.
26.
GunawardenaS, GoldsteinLSB (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron32, 389–401.
27.
SmallSA, GandyS (2006) Sorting through the cell biology of Alzheimer’s disease: Intracellular pathways to pathogenesis. Neuron52, 15–31.
28.
StamerK, VogelR, ThiesE, MandelkowE, MandelkowEM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol156, 1051–1063.
ChenZC, ZhangW, ChuaLL, ChaiC, LiR, LinL, CaoZ, AngelesDC, StantonLW, PengJH, ZhouZD, LimKL, ZengL, TanEK (2017) Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson’s disease. Sci Signal10, eaam6790.
34.
DicksonDW, KsiezakredingH, DaviesP, YenSH (1987) A monoclonal-antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol73, 254–258.
35.
MartinL, LatypovaX, WilsonCM, MagnaudeixA, PerrinML, YardinC, TerroF (2013) Tau protein kinases: Involvement in Alzheimer’s disease. Ageing Res Rev12, 289–309.
36.
DolanPJ, JohnsonGVW (2010) The role of tau kinases in Alzheimer’s disease. Curr Opin Drug Discov Devel13, 595–603.
37.
DicksonDW, Ksiezak-RedingH, DaviesP, YenSH (1987) A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol73, 254–258.
38.
KumarS, WirthsO, StuberK, WunderlichP, KochP, TheilS, Rezaei-GhalehN, ZweckstetterM, BayerTA, BrustleO, ThalDR, WalterJ (2016) Phosphorylation of the amyloid beta-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol131, 525–537.
